Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the Children's Oncology Group

Diagnostic mIBG (meta‐iodobenzylguanidine) scans are an integral component of response assessment in children with high‐risk neuroblastoma. The role of end‐of‐induction (EOI) Curie scores (CS) was previously described in patients undergoing a single course of high‐dose chemotherapy (HDC) and autologous hematopoietic cell transplant (AHCT) as consolidation therapy.

[1]  A. Naranjo,et al.  Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 , 2021, Clinical Cancer Research.

[2]  Jo Lynne Rokita,et al.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma , 2020, Cancer Research.

[3]  M. Gaze,et al.  Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1) , 2020, Cancers.

[4]  Chuan He,et al.  Progress toward liquid biopsies in pediatric solid tumors , 2019, Cancer and Metastasis Reviews.

[5]  A. Naranjo,et al.  Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. , 2019, JAMA.

[6]  A. Naranjo,et al.  A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 , 2018, Front. Immunol..

[7]  A. Naranjo,et al.  Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). , 2018, European journal of cancer.

[8]  A. Naranjo,et al.  Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  K. McHugh,et al.  Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Drobics,et al.  123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  B. Hero,et al.  MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  A. Naranjo,et al.  Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children’s Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1 , 2014, The Journal of Nuclear Medicine.

[13]  A. Naranjo,et al.  Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group , 2013, The Journal of Nuclear Medicine.

[14]  F. Berthold,et al.  Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Naranjo,et al.  A Pilot Study of Tandem High Dose Chemotherapy with Stem Cell Rescue as Consolidation for High Risk Neuroblastoma: Children’s Oncology Group study ANBL00P1 , 2012, Bone Marrow Transplantation.

[16]  M. Segal,et al.  Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group , 2012, International journal of molecular imaging.

[17]  F. Berthold,et al.  Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[19]  K. Matthay,et al.  Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force , 2010, British Journal of Cancer.

[20]  K. Matthay,et al.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  F. Berthold,et al.  The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. , 2008, European journal of cancer.

[22]  B. Shulkin,et al.  Current concepts on the diagnostic use of MIBG in children. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  E. Lanino,et al.  Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma. , 1995, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[24]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  E. Connolly,et al.  Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. , 2006, Neurosurgery.

[27]  B. Asselain,et al.  A new 123I-MIBG whole body scan scoring method--application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. , 1995, European journal of cancer.

[28]  J. Lumbroso,et al.  Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. , 1988, Progress in clinical and biological research.

[29]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.